New hope for Hard-to-Treat cancers: QLS1317 enters human testing
NCT ID NCT07552376
First seen May 04, 2026 · Last updated May 19, 2026 · Updated 3 times
Summary
This early-phase study tests a new drug called QLS1317 in about 120 adults with advanced solid tumors that have high microsatellite instability (MSI-H) or a DNA repair defect (dMMR) and have stopped responding to standard treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Participants must be 18 or older, in fair health, and have at least one measurable tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H OR DMMR ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.